摘要
目的探讨标准三联疗法复合Boulardii酵母菌对根除幽门螺杆菌(helicobacter pylori,Hp)疗效的影响及其对治疗中不良反应的改善情况进行系统评价.方法 Hp阳性的慢性胃炎、消化性溃疡患者120例,随机分成对照组(65例)、试验组(55例).对照组给予克拉霉素、阿莫西林、潘托拉唑三联治疗14 d,试验组在上述标准三联、14 d疗法基础上连续加用Boulardii酵母菌,在完成根除Hp的治疗后第5周进行14C-UBT复查,比较各组的Hp根除率、药物不良反应发生率,试验结果阴性患者在治疗结束后第3、6、9、12个月复查14C-尿素呼气试验.结果 120例患者按试验设计完成治疗,108例患者按试验设计完成随访,试验组(92.7%)根除率显著高于对照组(58.5%),差异有统计学意义(P<0.05),试验组(21.8%)不良反应发生率显著低于对照组(73.8%),差异有统计学意义(P<0.05);对照组Hp累积复发率(7.2±4.2)%较实验组(1.4±0.9)%显著升高(P<0.05).结论联用Boulardii酵母菌能显著提高Hp根除率,降低其不良反应.
Objective To evaluate the clinical efficacy of triple therapy with Saccharomyces boulardii in Helicobacter pylori（H. pylori） eradication.Methods One hundred and twenty H. pylori-positive patients with chronic gastritis or peptic ulcer were randomly divided into control group and experimental group. The control group underwent standard triple therapy（clarithromycin, amoxicillin and Pantoprazole for 14d）, Saccharomyces boulardii were additionally given to experimental group. The 14 C urea breath test was performed 1 wk after all drugs were stopped. The rate of H. pylori eradication and safety were evaluated.Results.In total, 120 patients completed the treatment and 108 patients completed the follow-up according to the experimental design. The eradication rate was significantly higher in the experimental group than in the control group（92.7% vs 58.5%,P〈0.05）. Adverse reactions were slight in all the groups, and there was significant difference in the rate of adverse reactions between the experimental group and the control group（21.8 vs 73.8,P〈0.05）. The accumulative recurrent rate in treatment group（1.4%±0.9%） was significantly lower than that in control group（7.2±4.2） %,P〈0.05.Conclusion Saccharomyces boulardii with triple therapy can improve the rate of H. pylori eradication and reduce the incidence of adverse reactions.
出处
《昆明医科大学学报》
CAS
2014年第10期122-126,共5页
Journal of Kunming Medical University
